Prognostic Value of High Sensitive Troponin T in Patients with Chronic Ischemic Heart Disease Undergoing Percutaneous Coronary Intervention

Basit Öğe Kaydı
dc.contributor.authorAktas, Halil
dc.contributor.authorKaypakli, Onur
dc.contributor.authorOzmen, Caglar
dc.contributor.authorGul, Murat
dc.contributor.authorYildirim, Oguz
dc.contributor.authorInci, Sinan
dc.contributor.authorDeniz, Ali
dc.date.accessioned2024-09-18T20:08:25Z
dc.date.available2024-09-18T20:08:25Z
dc.date.issued2021
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractObjective: Several studies have investigated different cardiac biomarkers as predictors of the prognosis after percutaneous coronary interventions (PCI) in patients with chronic ischemic heart disease; nevertheless, the results of these studies are conflicting. High sensitive troponin T (Hs-TnT) measurement is a novel and sensitive method. The aim of this study was to investigate if Hs-TnT levels are a predictor of major adverse cardiovascular events (MACE) in the first year after a successful elective PCI in patients with stable angina pectoris (SAP). Material and methods: 100 patients who presented with SAP and underwent successfully elective PCI were included in the study. Patients with elevated troponin I levels (>0.1 ng/mL) before the procedure excluded from the study. Hs-TnT levels were measured before the procedure and at 3-4 hours (h) (early period) and 12-24 hours (late period) after the procedure and Hs-TnT level >14 pg/mL was considered positive. The incidence of MACE during the first year was recorded. Results: Hs-TnT levels were positive in 36% of the patients in the early period and in 54% of the patients in the late period. The incidence rate of MACE for the first year was significantly higher in the patients with positive Hs-TnT levels in the early period but not the late period (36.1% vs. 15.6%; p = 0.026) and logistic regression analysis yielded an odds ratio of 3.36. Conclusion: Hs-TnT levels measured 3-4 h after a successful elective PCI in patients with SAP can predict the incidence of MACE within the first year. Nonetheless, these results must be corroborated by other larger studies.en_US
dc.identifier.doi10.33678/coL2020.082
dc.identifier.endpage39en_US
dc.identifier.issn0010-8650
dc.identifier.issn1803-7712
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85102820010en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage32en_US
dc.identifier.urihttps://doi.org/10.33678/coL2020.082
dc.identifier.urihttps://hdl.handle.net/20.500.12483/8823
dc.identifier.volume63en_US
dc.identifier.wosWOS:000623326100006en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherCzech Soc Cardiology & Czech Soc Cardiovascular Surgeryen_US
dc.relation.ispartofCor Et Vasaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChronic ischemic heart diseaseen_US
dc.subjectHigh sensitive troponin Ten_US
dc.subjectMajor adverse cardiovascular eventsen_US
dc.subjectPercutaneous coronary interventionen_US
dc.subjectPrognosisen_US
dc.titlePrognostic Value of High Sensitive Troponin T in Patients with Chronic Ischemic Heart Disease Undergoing Percutaneous Coronary Interventionen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ N/A ]
İsim:
Tam Metin / Full Text
Boyut:
95.8 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu